958635-19-3

Usage

Uses

Used in Pharmaceutical Industry:
(S)-1,4-di-Boc-piperazine-2-carboxylic acid Methyl ester is utilized as a key intermediate in the synthesis of various drug molecules. Its unique structure allows for the development of pharmaceuticals with potential therapeutic effects, making it a valuable component in medicinal chemistry.
Used in Organic Synthesis:
In the field of organic synthesis, (S)-1,4-di-Boc-piperazine-2-carboxylic acid Methyl ester serves as a versatile building block for the creation of other organic molecules. Its functional groups can be selectively modified to produce a range of compounds with different properties and applications, contributing to the advancement of chemical research and development.
Used in Drug Design and Development:
(S)-1,4-di-Boc-piperazine-2-carboxylic acid Methyl ester is employed as a starting material in drug design and development processes. Its ability to be modified and incorporated into complex molecular structures makes it a promising candidate for the creation of new pharmaceuticals with improved efficacy and selectivity.

Upstream product

• 788799-69-9 (2S)-1,4-bis(tert-butoxycarbonyl)piperazine-2-carboxylic acid 
• 74-88-4 methyl iodide 
• 796096-64-5 (S)-piperazine-1,2-dicarboxylic acid 1-tert-butyl ester 2-methyl ester 
• 24424-99-5 di-tert-butyl dicarbonate 
• 147650-70-2 (2S)-piperazine-2-carboxylic acid 

Downstream Products

• 314741-40-7 (3S)-3-(hydroxymethyl)-1-piperazinecarboxylic acid 1,1-dimethylethyl ester 
• 958635-18-2 tert-butyl (8aS)-3-oxotetrahydro-1,3-oxazolo[3,4-a]pyrazine-7(1H)-carboxylate 

Relevant academic research and scientific papers

ANTAGONIST COMPOUNDS

The present invention relates to compounds of formula (I) shown below: wherein R1, R2, R3, R4, R5 and R6 are each as defined in the application. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of diseases or conditions in which adenosine A2a and/or A2b receptor activity is implicated, such as, for example, cancer.

ANTAGONISTS OF THE ADENOSINE A2A RECEPTOR

The present invention relates to compounds of formula I shown below: wherein R0, R1, R2, R3 and A are each as defined in the application. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of diseases or conditions in which adenosine A2a receptor activity is implicated, such as, for example, cancer.

PYRAZOLOPYRIDINE KINASE INHIBITORS

The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, co

TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS

The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, co

A practical synthesis of differentially protected 2-(Hydroxymethyl) piperazines

(Chemical Equation Presented) An efficient and scalable synthesis of three differentially protected 2-(hydroxymefhyl)piperazines is presented, starting from optically active and commercially available (2S)-piperazine-2-carboxylic acid dihydrochloride. These synthetic building blocks are useful in the preparation of biologically active compounds and as chemical scaffolds for the construction of combinatorial libraries.